Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-β-nitrostyrene, a novel tyrosine kinase inhibitor

Molecular Pharmacology

Volumn 70, Issue 4, 2006, Pages 1380-1389

  Wang, Wei Ya ^a   Wu, Yang Chang ^a   Wu, Chin Chung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXY BETA NITROSTYRENE; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CALCIUM; CALPAIN; CYCLIC NUCLEOTIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; MYOSIN LIGHT CHAIN KINASE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARACHIDONIC ACID METABOLISM; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

BLOOD PLATELETS; CALCIUM; CALPAIN; CELLS, CULTURED; CYTOSKELETON; DIOXOLANES; DRUG EVALUATION; HUMANS; MOLECULAR STRUCTURE; MYOSIN-LIGHT-CHAIN KINASE; NUCLEOTIDES, CYCLIC; P-SELECTIN; PHOSPHOLIPASE C GAMMA; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TALIN; THROMBIN; THROMBOXANES;

EID: 33748933392     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.023986     Document Type: Article

References (44)

1. Andre P (2004) P-selectin in haemostasis. Br J Haematol 126:298-306.
2. Antiplatelet Trialists' Collaboration (1994a) Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106.
3. Antiplatelet Trialists' Collaboration (1994b) Collaborative overview of randomized trials of antiplatelet therapy II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308:159-168.
4. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86.
5. Asahi M, Yanagi S, Ohta S, Inazu T, Sakai K, Takeuchi F, Taniguchi T, and Yamamura H (1992) Thrombin-induced human platelet aggregation is inhibited by protein-tyrosine kinase inhibitors, ST638 and genistein. FEBS Lett 309:10-14.
6. Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A, and Chishti AH (2001) Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol 21:2213-2220.
7. Banno Y, Nakashima S, Ohzawa M, and Nozawa Y (1996) Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin-stimulated human platelets. J Biol Chem 271:14989-14994.
8. Bishop WR, Petrin J, Wang L, Ramesh U, and Doll RJ (1990) Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol 40:2129-2135.
9. Boersma E, Harrington RA, Moliterno DJ, White H, and Simoons ML (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet 360:342-343.
10. Croce K, Flaumenhaft R, Rivers M, Furie B, Furie BC, Herman IM, and Potter DA (1999) Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem 274:36321-36327.
11. Elzagallaai A, Rose SD, and Trifaro JM (2000) Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-derived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation. Blood 95:894-902.
12. Furman MI, Grigoryev D, Bray PF, Dise KR, and Goldschmidt-Clermont PJ (1994) Platelet tyrosine kinases and fibrinogen receptor activation. Circ Res 75:172-180.
13. Gibbins JM (2004) Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117:3415-3425.
14. Haslam RJ, Dickinson NT, and Jang EK (1999) Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 82:412-423.
15. Hers I, Donath J, van Willigen G, and Akkerman JW (1998) Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure. Arterioscler Thromb Vasc Biol 18:404-414.
16. 2+ signaling. Blood 92:3675-3683.
17. Jackson SP, Nesbitt WS, and Kulkarni S (2003) Signaling events underlying thrombus formation. J Thromb Haemost 1:1602-1612.
18. Jackson SP, Schoenwaelder SM, Yuan Y, Salem HH, and Cooray P (1996) Non-receptor protein tyrosine kinases and phosphatases in human platelets. Thromb Haemost 76:640-650.
19. Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, Shattil SJ, Ginsberg MH, Tybulewicz VL, and Phillips DR (1999) Genetic and pharmacological analyses of Syk function in αIIbβ3 signaling in platelets. Blood 93:2645-2652.
20. Leclerc JR (2002) Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med 30:S332-S340.
21. Levy-Toledano S (1999) Platelet signal transduction pathways: could we organize them into a 'hierarchy'? Haemostasis 29:4-15.
22. Lundblad RL and White GC (2005) The interaction of thrombin with blood platelets. Platelets 16:373-385.
23. McNicol A (1993) The effects of genistein on platelet function are due to thromboxane receptor antagonism rather than inhibition of tyrosine kinase. Prostaglandins Leukot Essent Fatty Acids 48:379-384.
24. 2+ in platelets and neutrophils. Biochem J 269:513-519.
25. Murugappan S, Shankar H, Bhamidipati S, Dorsam RT, Jin J, and Kunapuli SP (2005) Molecular mechanism and functional implications of thrombin-mediated tyrosine phosphorylation of PKCdelta in platelets. Blood 106:550-557.
26. Nakashima S, Koike T, and Nozawa Y (1991) Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses. Mol Pharmacol 39:475-480.
27. Nozawa Y, Banno Y, and Nagata K (1993) Regulation of phosphoinositide- specific phospholipase C activity in human platelets. Adv Exp Med Biol 344:37-47.
28. Osusky M, Taylor SJ, and Shalloway D (1995) Autophosphorylation of purified c-Src at its primary negative regulation site. J Biol Chem 270:25729-25732.
29. 2+ mobilization in human platelets by affecting polyphosphoinositide turnover. Biochem Pharmacol 46:395-403.
30. Packham MA (1994) Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 72:278-284.
31. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, and Bode C (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood 92:3240-3249.
32. Pula G, Crosby D, Baker J, and Poole AW (2005) Functional interaction of protein kinase Cα with the tyrosine kinases Syk and Src in human platelets. J Biol Chem 280:7194-7205.
33. Quinn MJ, Byzova TV, Qin J, Topol EJ, and Plow EF (2003) Integrin αIIbβ3 and its antagonism. Arterioscler Thromb Vasc Biol 23:945-952.
34. Rendu F, Eldor A, Grelac F, Bachelot C, Gazit A, Gilon C, Levy-Toledano S, and Levitzki A (1992) Inhibition of platelet activation by tyrosine kinase inhibitors. Biochem Pharmacol 44:881-888.
35. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 11:1227-1234.
36. Santos MT, Moscardo A, Valles J, Martinez M, Pinon M, Aznar J, Broekman MJ, and Marcus AJ (2000) Participation of tyrosine phosphorylation in cytoskeletal reorganization, αIIbβ3 integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets. Circulation 102:1924-1930.
37. Schoenwaelder SM, Jackson SP, Yuan Y, Teasdale MS, Salem HH, and Mitchell CA (1994) Tyrosine kinases regulate the cytoskeletal attachment of integrin αIIbβ3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin polymers. J Biol Chem 269:32479-32487.
38. Schwarz UR, Walter U, and Eigenthaler M (2001) Taming platelets with cyclic nucleotides. Biochem Pharmacol 62:1153-1161.
39. Shattil SJ, Kashiwagi H, and Pampori N (1998) Integrin signaling: the platelet paradigm. Blood 91:2645-2657.
40. Shebuski RJ and Kilgore KS (2002) Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300:729-735.
41. Tuszynski GP, Kornecki E, Cierniewski C, Knight LC, Koshy A, Srivastava S, Niewiarowski S, and Walsh PN (1984) Association of fibrin with the platelet cytoskeleton. J Biol Chem 259:5247-5254.
42. van Willigen G, Hers I, Gorter G, and Akkerman JW (1996) Exposure of ligand-binding sites on platelet integrin alpha IIB/beta 3 by phosphorylation of the beta 3 subunit. Biochem J 314:769-779.
43. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Lee CY, and Teng CM (2003) The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost 90:299-308.
44. Wu CC, Wang WY, Kuo RY, Chang FR, and Wu YC (2004) Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases. Eur J Pharmacol 483:187-194.